Search Browse Earnings

Outlook Therapeutics, Inc.

Nasdaq:OTLK

Biological Products, (No Diagnostic Substances)·ISELIN, NJ

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Outlook Therapeutics, Inc. — SlamSEC

Revenue

$1.4M

FY 2025

Adj. EBITDA

-$68.3M

-4834.8% margin

FY 2025

Net Income

-$75.4M

-5331.8% margin

FY 2025

EPS (Diluted)

-$4.06

FY 2025

Stock Price

$0.41

-2.7%

2026-03-06

52W Range

$0.38 – $3.39

P/E Ratio

-0.1x

Market Cap

$34.4M

Cash

$14.9M

FY 2025

Total Debt

$841,133

FY 2019

Net Cash

$14.1M

FY 2019

Enterprise Value

$20.3M

Debt / EBITDA

0.2x

FY 2025

EV / EBITDA

-0.3x

Employees

—